Table 2. Association Between the Use of SGLT2i and the Risk of Overall Fractures Among Weighted Populations.
| Exposure | No. of patientsa | No. of Events | Person-years | Weighted IR (95% CI)b | Weighted HR (95% CI) |
|---|---|---|---|---|---|
| SGLT2i vs DPP4i | |||||
| SGLT2i | 37 530 | 768 | 54 619 | 1.41 (1.31-1.51) | 0.78 (0.72-0.84) |
| DPP4i | 332 004 | 18 800 | 693 818 | 1.81 (1.78-1.85) | 1.00 [Reference] |
| SGLT2i vs GLP1RA | |||||
| SGLT2i | 111 835 | 2723 | 164 967 | 1.67 (1.60-1.73) | 0.92 (0.68-1.24) |
| GLP1RA | 8177 | 156 | 6737 | 1.92 (1.59-2.30) | 1.00 [Reference] |
Abbreviations: DPP4i, dipeptidyl peptidase 4 inhibitors; GLP1RA, glucagon-like peptide 1 receptor agonists; HR, hazard ratio; IR, incidence rate; SGLT2i, sodium-glucose cotransporter 2 inhibitors.
a
Patients remained after trimming patients in the nonoverlapping regions of the propensity score distributions.
b
Per 100 person-years.